February 16, 2017
Vectura achieves royalty cap from GSK’s respiratory products
Vectura Group has reached a royalty cap on net sales of £9 million from selling GSK’s respiratory Ellipta products in 2016.
Pharmaceuticals, Biotechnology and Life Sciences
Tag: Ellipta